Rate My Professor Kim Chan

Since joining the University of Sydney over a decade ago, Professor Chan has authored more than 280 scientific publications, accumulating over 30,000 citations on Google Scholar with an h-index of 73. Notable publications include 'Spray Dried Powders and Powder Blends of Recombinant Human Deoxyribonuclease Using an Organic Solvent Free Process' (2001), 'Use of Solid Corrugated Particles to Enhance Powder Aerosol Performance' (2002), 'Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections' (2025), and 'Eradication of Pseudomonas aeruginosa using fixed-dose combination of probiotics and bacteriophages: development of an inhalable powder' (2025). His career includes prior roles as Researcher at Genentech (1992-1995) and Postdoctoral Fellow at the University of Minnesota Department of Pharmaceutics (1988-1989). Professor Chan has secured major funding, including ARC Linkage Grants, a US FDA grant over $500,000 in 2018 for inhaler development, and another FDA award in 2023 for affordable asthma inhalers. He holds the AAPS Fellowship and serves as Specialty Chief Editor for Respiratory Drug Delivery at Frontiers in Drug Delivery, as well as on the editorial board of the International Journal of Pharmaceutics. Additionally, he is a member of the University of Sydney Nano Institute and Sydney Infectious Diseases Institute.